Citius Oncology Faces Delisting Concerns
Ticker: CTOR · Form: 8-K · Filed: Apr 25, 2025 · CIK: 1851484
Sentiment: bearish
Topics: delisting, listing-standards, regulatory-filing
TL;DR
Citius Oncology might get delisted - big trouble ahead.
AI Summary
On April 23, 2025, Citius Oncology, Inc. filed an 8-K to report a notice of delisting or failure to satisfy a continued listing rule. The company, formerly known as TenX Keane Acquisition, is incorporated in Delaware and has its principal executive offices in Cranford, NJ.
Why It Matters
This filing indicates potential issues with Citius Oncology's continued listing on an exchange, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards is a severe warning sign for a company's financial health and operational viability.
Key Players & Entities
- CITIUS ONCOLOGY, INC. (company) — Registrant
- TenX Keane Acquisition (company) — Former company name
- April 23, 2025 (date) — Date of earliest event reported
- 001-41534 (other) — Commission File Number
- 11 Commerce Drive, 1st Floor, Cranford, NJ 07016 (location) — Principal executive offices address
FAQ
What specific listing rule or standard has Citius Oncology failed to satisfy?
The filing does not specify the exact rule or standard that Citius Oncology has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is April 23, 2025.
What was Citius Oncology, Inc. previously named?
Citius Oncology, Inc. was formerly named TenX Keane Acquisition.
In which state is Citius Oncology, Inc. incorporated?
Citius Oncology, Inc. is incorporated in Delaware.
What is the address of Citius Oncology's principal executive offices?
The address of Citius Oncology's principal executive offices is 11 Commerce Drive, 1st Floor, Cranford, NJ 07016.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 25, 2025 regarding CITIUS ONCOLOGY, INC. (CTOR).